X

Drug Profile

Ciaftalan zinc

Alternative Names: CGP 55847; Zinc phthalocyanine; ZnPc

Latest Information Update: 30 Nov 2016

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novartis
Class Antihyperlipidaemics; Antineoplastics; Heavy metals
Mechanism of Action Reactive oxygen species stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Cancer

Most Recent Events

29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
18 Mar 2003 Discontinued - Phase-I for Cancer in European Union (unspecified route)
13 Mar 1997 A preclinical study has been added to the pharmacodynamics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com